News: Portfolio 2007
Agile Therapeutics Expands Senior Management Team
(continued)
"We've been able to assemble a very high performing team to manage the progress of our lead product in the development process," said Thomas M. Rossi, Ph.D., CEO and President of Agile Therapeutics. "These key additions will help us achieve our vision of bringing value to women who want an easy- to-use contraceptive with the advantages of a low estrogen dosing profile."
Agile Therapeutics' contraceptive patch is currently in phase 2 clinical development. The company is privately held and supported by high-quality health care investors, including ProQuest, a healthcare venture capital firm that is managing over $875 million; the Hillman Company and its Affiliates, a diversified investment firm active in venture capital investing for over 25 years; TL Ventures, with over $1.4 billion under management; and PA Early Stage Partners, with more than $235 million under management.